Our goal is to be the leading global biopharmaceutical company focused on the innovative treatment of women’s health diseases and other endocrine-related disorders in areas of high unmet medical need, and improve the lives of millions of patients suffering from these diseases.
Our lead program is relugolix, a phase 3 drug candidate that has been evaluated in over 1,300 patients to date. Relugolix has successfully demonstrated significant clinical benefit and was generally well-tolerated across large, randomized phase 2 clinical trials in uterine fibroids, endometriosis and prostate cancer. In addition, we are developing MVT-602 for the treatment of female infertility in in-vitro fertilization. Over time, we intend to expand our development pipeline to include other potential treatments for endocrine-related disorders.